AnaptysBio (ANAB) News Today → Log Into Marc's $5,000 System Today (From Chaikin Analytics) (Ad) Free ANAB Stock Alerts $23.36 -0.55 (-2.30%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 27 at 6:18 AM | americanbankingnews.comInsider Selling: AnaptysBio, Inc. (NASDAQ:ANAB) CFO Sells $35,580.00 in StockMay 26 at 1:50 AM | americanbankingnews.comAnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by AnalystsMay 26 at 1:49 AM | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Rating of "Moderate Buy" from BrokeragesAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation toMay 25 at 4:34 PM | insidertrades.comDennis Mulroy Sells 1,500 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) StockMay 24, 2024 | marketbeat.comInsider Selling: AnaptysBio, Inc. (NASDAQ:ANAB) CFO Sells 1,500 Shares of StockAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) CFO Dennis Mulroy sold 1,500 shares of the company's stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $23.72, for a total transaction of $35,580.00. Following the completion of the transaction, the chief financial officer now owns 964 shares in the company, valued at $22,866.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.May 22, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Trading Up 6.6%AnaptysBio (NASDAQ:ANAB) Stock Price Up 6.6%May 22, 2024 | finance.yahoo.comIndustry Analysts Just Upgraded Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts By 16%May 19, 2024 | finance.yahoo.comAnaptysBio, Inc. (ANAB)May 10, 2024 | benzinga.comThe Analyst Landscape: 7 Takes On AnaptysBioMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for AnaptysBio Amidst Promising Pipeline and Strategic Financial PositioningMay 10, 2024 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on AnaptysBio (ANAB)May 10, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Earns Outperform Rating from WedbushWedbush restated an "outperform" rating and issued a $34.00 price target on shares of AnaptysBio in a research note on Friday.May 10, 2024 | finanznachrichten.deAnaptysBio, Inc.: Anaptys Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | msn.comANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | globenewswire.comAnaptys Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | globenewswire.comAnaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)May 9, 2024 | globenewswire.comAnaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli RoyaltiesMay 6, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Stock Price Down 3.3%AnaptysBio (NASDAQ:ANAB) Stock Price Down 3.3%May 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for AnaptysBio on Positive Development Outlook and Market PotentialApril 30, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Sees Strong Trading VolumeAnaptysBio (NASDAQ:ANAB) Sees Large Volume IncreaseApril 26, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Stock Price Up 8.2%AnaptysBio (NASDAQ:ANAB) Trading Up 8.2%April 24, 2024 | prnewswire.comActym Therapeutics Appoints Thomas Smart as CEOApril 18, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Trading Down 5.9%AnaptysBio (NASDAQ:ANAB) Shares Down 5.9%April 18, 2024 | marketbeat.comQ1 2024 Earnings Estimate for AnaptysBio, Inc. Issued By Leerink Partnrs (NASDAQ:ANAB)AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for AnaptysBio in a research note issued to investors on Tuesday, April 16th. Leerink Partnrs analyst D. Risinger expects that the biotechnology company will post earningsApril 17, 2024 | msn.comLeerink Partners Initiates Coverage of AnaptysBio (ANAB) with Outperform RecommendationApril 16, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Trading Up 3.6%AnaptysBio (NASDAQ:ANAB) Trading 3.6% HigherApril 15, 2024 | investorplace.comBTIG Research Predicts Over 118% Rally for These 3 StocksApril 12, 2024 | fool.comWhy AnaptysBio Stock Zoomed Nearly 8% Higher This WeekApril 12, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Stock Price Down 8.2%AnaptysBio (NASDAQ:ANAB) Trading Down 8.2%April 12, 2024 | marketbeat.comVanguard Group Inc. Sells 72,916 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)Vanguard Group Inc. lowered its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 4.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,702,781 shares of the biotechnology company's stock after selliApril 11, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Research Coverage Started at Wells Fargo & CompanyWells Fargo & Company started coverage on AnaptysBio in a report on Thursday. They issued an "overweight" rating and a $56.00 price target on the stock.April 10, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Trading 3.2% Higher AnaptysBio (NASDAQ:ANAB) Shares Up 3.2%April 6, 2024 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and five have giApril 4, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Trading Up 4%AnaptysBio (NASDAQ:ANAB) Trading 4% HigherApril 1, 2024 | markets.businessinsider.comUnveiling 4 Analyst Insights On AnaptysBioApril 1, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Stock Price Down 4.6% Following Analyst DowngradeAnaptysBio (NASDAQ:ANAB) Stock Price Down 4.6% After Analyst DowngradeMarch 27, 2024 | insidertrades.comDaniel Faga Sells 3,000 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) StockMarch 26, 2024 | marketbeat.comInsider Selling: AnaptysBio, Inc. (NASDAQ:ANAB) CEO Sells 3,000 Shares of StockAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) CEO Daniel Faga sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the transaction, the chief executive officer now directly owns 749,087 shares of the company's stock, valued at approximately $16,045,443.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.March 22, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Stock Price Down 5.1%AnaptysBio (NASDAQ:ANAB) Shares Down 5.1%March 18, 2024 | finance.yahoo.comIndustry Analysts Just Made A Stunning Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue ForecastsMarch 18, 2024 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Short Interest UpdateAnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) was the recipient of a significant decline in short interest in February. As of February 29th, there was short interest totalling 4,200,000 shares, a decline of 6.9% from the February 14th total of 4,510,000 shares. Based on an average daily trading volume, of 264,500 shares, the days-to-cover ratio is presently 15.9 days. Approximately 18.3% of the shares of the stock are short sold.March 17, 2024 | marketbeat.comHudson Bay Capital Management LP Increases Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)Hudson Bay Capital Management LP increased its holdings in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 100.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100,000 shares of the biotechnology compaMarch 14, 2024 | marketbeat.comQ1 2024 EPS Estimates for AnaptysBio, Inc. Lifted by Analyst (NASDAQ:ANAB)AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Equities researchers at Wedbush boosted their Q1 2024 earnings per share (EPS) estimates for AnaptysBio in a research note issued on Tuesday, March 12th. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will post earningMarch 13, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Trading Down 3.8%AnaptysBio (NASDAQ:ANAB) Trading Down 3.8%March 12, 2024 | markets.businessinsider.comSkin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical TriggersMarch 12, 2024 | seekingalpha.comWedbush raises AnaptysBio to outperform, cites upcoming dataMarch 12, 2024 | markets.businessinsider.comJ.P. Morgan Reaffirms Their Hold Rating on AnaptysBio (ANAB)March 12, 2024 | finanznachrichten.deAnaptysBio, Inc.: Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 12, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Raised to "Outperform" at WedbushWedbush upgraded AnaptysBio from a "neutral" rating to an "outperform" rating and raised their target price for the stock from $20.00 to $34.00 in a research report on Tuesday.March 11, 2024 | globenewswire.comAnaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Log Into Marc's $5,000 System Today (Ad)New Panic Could Sweep America Mark these words in 2024. Everyone's going to cash… Wall Street legend says: "A little-known vehicle outside of banks could double… triple… or even quadruple your life savings if you know where to find it right now." We urge you to move your cash into this vehicle in 2024. More here. ANAB Media Mentions By Week ANAB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANAB News Sentiment▼0.850.87▲Average Medical News Sentiment ANAB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANAB Articles This Week▼102▲ANAB Articles Average Week Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Pharvaris News Today Lyell Immunopharma News Today GH Research News Today Mineralys Therapeutics News Today ArriVent BioPharma News Today Calliditas Therapeutics AB (publ) News Today Zymeworks News Today Phathom Pharmaceuticals News Today Pharming Group News Today Arbutus Biopharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANAB) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDigitizing the $11T commodities sector with one tiny stockResource Stock DigestBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesBitcoin’s Biggest Year YetParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
